This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Abcam
other brands :
Epitomics, Ascent Scientific, MitoSciences
product type :
antibody
product name :
LAMP2 antibody [ABL-93] - Lysosome Marker
catalog :
ab25339
quantity :
100 ug
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
ABL-93
reactivity :
human, mouse, rat
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry
citations: 10
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
| |
| Harris White M, Ferbas K, Johnson M, Eslami P, Poteshkina A, Venkova K, et al. A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies. Neurobiol Dis. 2015;84:60-8 pubmed publisher
|
| |
| |
Sun Y, Liou B, Ran H, Skelton M, Williams M, Vorhees C, et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010;19:1088-97 pubmed publisher
| |
Cardone M, Polito V, Pepe S, Mann L, D AZZO A, Auricchio A, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet. 2006;15:1225-36 pubmed
|
product information
Catalog Number :
ab25339
Product Name :
LAMP2 antibody [ABL-93] - Lysosome Marker
Host Species :
Rat
Clonality :
monoclonal
Product Type :
Primary antibodies
Size :
100 ug
Isotype :
IgG2a
CrossReactivity :
Reacts with: Mouse.
Application Summary :
Flow Cyt, IHC-Fr, IP, WB
company information

Abcam
Discovery Drive
Cambridge Biomedical Campus
Cambridge
CB20AX
https://www.abcam.comCambridge Biomedical Campus
Cambridge
CB20AX
888-7722226
headquarters: UK
questions and comments